Safety, tolerability, and how the body handles SK-08 in healthy adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1, single-center, randomized, double-blind, placebo-controlled, dose-escalation trial plans to enroll up to 48 healthy volunteers across seven predefined dose cohorts (A1–A7). Participants will be randomized to receive SK-08 or placebo with blinded dosing and close safety monitoring. Serial blood sampling will characterize pharmacokinetics and pharmacodynamics, and adverse events and laboratory tests will evaluate tolerability. Findings will inform safe dose ranges and timing for subsequent patient trials in chronic kidney disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Healthy male and female participants aged 18 to 45 years (inclusive).
2. Male participants: Body weight ≥50 kg; Female participants: Body weight ≥45 kg; Body mass index (BMI) between 19.0 and 26 kg/m².
3. Participants must have no plans for conception during the trial and for 3 months after the last dose, and must voluntarily use effective contraception with no plans for sperm or egg donation .
4. Capable of understanding and voluntarily providing written informed consent prior to any study-related procedures.

Exclusion Criteria:

1. Have a specific history of allergies or have an allergic constitution；
2. Have a history of chronic diseases or severe diseases in the cardiovascular, liver, kidney, biliary tract, respiratory, blood and lymphatic, endocrine, immune, mental, neuromuscular, gastrointestinal systems, etc.
3. Developed acute diseases from 2 weeks before screening to before randomization ;
4. Patients with previous or current hypotension or insufficient blood volume, intracranial hypertension or cerebral hemorrhage, or those with ocular diseases (such as angle-closure glaucoma), who are not suitable for inclusion after assessment by the researcher;
5. Those with clinical significance hypokalemia, hyperkalemia, hypomagnesemia, hypermagnesemia, hypocalcemia, and hypercalcemia;
6. Those who have used any drugs or health supplements from 2 weeks before screening to randomization ;
7. Any drugs that may interact with this product have been used from 30 days before screening to randomization, such as CYP450 inhibitors or inducers ;
8. Those who have undergone major surgical operations from 6 months before screening , or who plan to undergo surgery during the study period, or who have undergone surgeries as judged by the investigator to affect drug absorption, distribution, metabolism, and excretion;
9. Those who have received live attenuated vaccine inoculation from 2 weeks before screening to randomization or those who need to receive live attenuated vaccine inoculation during the trial;
10. Those who had a history of alcohol abuse within one year before screening；
11. Those who smoked more than 5 cigarettes per day on average within 3 months before screening and before randomization, or were unable to stop using any tobacco products during the trial period;
12. Those who cannot tolerate venipuncture/indwelling needles or have a history of fainting from needles or blood ;
13. Other researchers determined that the subjects were not suitable to participate.

Where it's running

• The First Affiliated Hospital，Zhejiang University
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: JIAN LIU, Master
• Email: lindaliu87@zju.edu.cn
• Phone: 13958054006

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Biomarker-guided treatment strategy for chronic kidney disease

  This trial will test whether using urine biomarkers to guide adding dapagliflozin, finerenone, and/or semaglutide can better reduce albuminuria and protect kidneys in adults with CKD.

  Recruiting Phase 4 Steno Diabetes Center Copenhagen · Herlev and 3 other locations · NCT07239570

• Algae supplements for heart risk markers and gut health

  This trial will test whether daily supplements of spirulina or Gelidium corneum change gut microbes and improve heart‑disease risk markers in adults over 50 with cardiovascular disease, diabetes, or related conditions.

  Recruiting Universidade do Porto · Porto · NCT07173062

• Validating lab assays, IV catheter techniques, and devices for endocrine, cardiometabolic, and musculoskeletal conditions

  This project will test whether laboratory assays, IV catheter methods, and equipment give consistent, reliable results in adults with or without obesity-related, metabolic, or musculoskeletal conditions.

  Recruiting University of Missouri-Columbia · Columbia, Missouri · NCT07083557

• Heart, kidney, and metabolic health in Shanghai community residents

  This follow-up will track people from the STONE cohort to see if changes in metabolic risk factors over time relate to heart and kidney outcomes.

  Recruiting Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT07043166

• How common high potassium is and what increases the risk in non-dialysis CKD patients in the community

  This project will test how common high potassium is and try to find which health and lifestyle factors raise the risk in adults with chronic kidney disease who are not on dialysis.

  Recruiting Songjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine · Shanghai, Shanghai Municipality · NCT06940414

• Using a plant-based low protein diet to manage chronic kidney disease

  This study is testing if a plant-based low protein diet can help people with chronic kidney disease manage their condition better than a standard diet.

  Recruiting Lebanese American University · Beirut · NCT06932042

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.